[This corrects the article DOI: 10.3389/fphar.2018.00022.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108601 | PMC |
| http://dx.doi.org/10.3389/fphar.2021.605592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune Encephalomyelitis." [Experimental and Molecular Pathology. 2014; 97(3):470-6. doi: 10.1016/j.yexmp.2014.10.004.].
Exp Mol Pathol
February 2023
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
Corrigendum: A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5.
Front Pharmacol
March 2021
Department of Orthopedics, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
[This corrects the article DOI: 10.3389/fphar.2018.
View Article and Find Full Text PDF[Corrigendum] The specific killing effect of matrine on castration‑resistant prostate cancer cells by targeting the Akt/FoxO3a signaling pathway.
Oncol Rep
December 2020
Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, P.R. China.
Subsequently to the publication of the article, the authors have realized that some errors were contained therein that went uncorrected before the paper was sent to press. First, Fig. 4 contained a pair of data panels that had been misplaced: The LY294002, PC‑3 data panel in Fig.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!